Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer.

Basade, M; Singhal, M; Rathi, A K; Nandi, M; Minhas, S; Goswami, C; Shinde, S; Parikh, P M; Aggarwal, S

Basade, M; Singhal, M; Rathi, A K; Nandi, M; Minhas, S; Goswami, C; Shinde, S; Parikh, P M; Aggarwal, S.

Afiliación

Basade M; Department of Medical Oncology, Saifee Hospital, Mumbai, Maharashtra, India.
Singhal M; Department of Medical Oncology, Indraprastha Apollo Hospital, New Delhi, India.
Rathi AK; Department of Radiation Oncology, MAMC, New Delhi, India.
Nandi M; Department of Medical Oncology, Jaypee Hospital, Noida, Uttar Pradesh, India.
Minhas S; Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India.
Goswami C; Department of Medical Oncology, Jaypee Hospital, Noida, Uttar Pradesh, India.
Shinde S; Department of Radiation Oncology, Medica Superspecialty Hospital, Kolkata, West Bengal, India.
Parikh PM; Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra, India.
Aggarwal S; Department of Radiation Oncology, Medica Superspecialty Hospital, Kolkata, West Bengal, India.

South Asian J Cancer ; 7(2): 146-150, 2018.

Article en En | MEDLINE | ID: mdl-29721483

Palabras clave

Capecitabine; TDM1; combination systemic therapy; docetaxel; lapatinib; personalized modification; pertuzumab; trastuzumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: South Asian J Cancer Año: 2018 Tipo del documento: Article País de afiliación: India Pais de publicación: India

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google